E-ISSN 2602-3164
EJMI. 2024; 8(2): 113-118 | DOI: 10.14744/ejmi.2024.14917

Pretreatment HALP Score Predicts Prognosis in Patients with Esophageal Cancer Treated with Chemoradiotherapy

Zehra Sucuoğlu İşleyen1, Mehmet Beşiroğlu1, Melih Şimşek1, Ayşe İrem Yasin1, Atakan Topçu1, Adem Akçakaya2, Mesut Seker1, Hacı Mehmet Türk1
1Department of Medical Oncology, Bezmialem Vakif University, Istanbul, Türkiye, 2Department of General Surgery, Bezmialem Vakif University, Istanbul, Türkiye

Objectives: We aimed to evaluate the relation of the pre-treatment hemoglobin-albumin-lymphocyte-platelet (HALP) score with survival and prognosis of locally advanced esophageal squamous cell carcinoma (ESCC) patients receiving chemoradiotherapy (CRT). Methods: We retrospectively included 45 patients with esophageal squamous cell carcinoma who were treated with chemoradiotherapy. The HALP score was calculated as hemoglobin level (g/L)*albumin level (g/L)*lymphocyte count (/L)/platelet count(/L). Results: According to the receiver operating characteristic (ROC) curve, the median of the HALP score was 42.36. Ac cording to this value, the patients were divided into two groups; Group 1 included 28 patients who had a HALP score <42.36 and Group 2 included 17 patients who had a HALP score >42.36. Median OS was 20.5 months in Group 1 and the median OS was not reached in Group 2 (p=0.033). Median PFS in all patient groups was 15.2 months. The median PFS was 12.2 months in Group 1 and 30.9 months in Group 2 (p=0.127). Univariate Cox regression analysis showed that pre-treatment low levels of HALP were associated with a short median time of OS (p=0.042). Conclusion: Our study suggested that pretreatment low HALP score was associated with poor OS in patients with lo cally advanced ESCC who were treated with CRT. Keywords: Esophageal cancer, hemoglobin-albumin-lymphocyte-platelet (HALP) score, overall survival (OS)


Cite This Article

Sucuoğlu İşleyen Z, Beşiroğlu M, Şimşek M, Yasin A, Topçu A, Akçakaya A, Seker M, Türk H. Pretreatment HALP Score Predicts Prognosis in Patients with Esophageal Cancer Treated with Chemoradiotherapy. EJMI. 2024; 8(2): 113-118

Corresponding Author: Zehra Sucuoğlu İşleyen

Full Text PDF PDF Download
EJMI & EJMI